New TAVR valve for native aortic regurgitation linked to positive 30-day outcomes

The J-Valve manufactured by JC Medical, a Genesis MedTech company, includes a self-expanding nitinol frame, bovine pericardial leaflets and three anchor rings designed to assist operators with alignment. Its delivery system was built with transfemoral access in mind, and JC Medical plans to offer the valve in five different sizes.

Structural heart specialists from The Christ Hospital. This team participated in a new EFS study focused on the J Valve from JC Medical. Image courtesy of JC Medical, a Genesis MedTech company, and The Christ Hospital.

The J Valve from JC Medical was linked to positive outcomes and “excellent” hemodynamic data after 30 days in an early feasibility study published in JACC: Cardiovascular Interventions. Researchers noted that the valve showed potential in patients with large aortic annuli, which represents an "unmet critical need" at this stage.